Esperion Therapeutics Shares Are Trading Higher After the Company Announced That Its European Partner, Daiichi Sankyo Europe, Reported Final 2-year Follow-up Data From the German Cohort of the Multinational, European Observational MILOS Study.
Esperion Therapeutics Shares Are Trading Higher After the Company Announced That Its European Partner, Daiichi Sankyo Europe, Reported Final 2-year Follow-up Data From the German Cohort of the Multinational, European Observational MILOS Study.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated